Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hengrui Approved to Launch Antifungal for Vulvovaginal Candidiasis

publication date: Aug 22, 2023

Jiangsu Hengrui Pharma was approved to launch an azole antifungal to treat severe vulvovaginal candidiasis, commonly known as yeast infections. A novel oral therapy, Oteseconazole Capsules are designed to have greater selectivity, fewer side effects and improved potency than current treatments. The therapy may also be effective for other systemic fungal infections. In 2019, Hengrui in-licensed greater China rights for Oteseconazole Capsules from Mycovia Pharma of North Carolina. It signed a standard pact with Mycovia for the rights, including upfront, milestone and royalty payments, though specific details of the agreement were not disclosed. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital